Ustekinumab [Stelara]
Yes
No
No
Active ingredient: Ustekinumab
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
06/02/2026 Ustekinumab biosimilar for treating inflammatory conditions
The Ministry of Health’s Drug Advisory Committee has recommended ustekinumab biosimilar (Steqeyma) 45 mg/0.5 mL pre-filled syringe, 90 mg/1 mL pre-filled syringe, and 130 mg/26 mL vial for listing on the MOH Standard Drug List (SDL). The decision was based on the acceptable pricing proposal from the company.
Funding status
[R] SDL subsidy will apply from 1 April 2026 to all registered indications of ustekinumab biosimilar (Steqeyma) 45 mg/0.5 mL pre-filled syringe, 90 mg/1 mL pre-filled syringe, and 130 mg/26 mL vial in Singapore.
[NR] SDL subsidy does not apply to other brand(s), formulation(s) or strength(s) of ustekinumab.
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Stelara Injection, Solution 45 mg/0.5 mL |
|
Stelara Injection, Solution (Pre-Filled Syringe) 90 mg/1 mL |
|
Stelara Infusion, Solution Concentrate 130 mg/vial |
|
Stelara Injection, Solution (Pre-Filled Pen) 90 mg/1 mL |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Intravenous
* Clinical information is available for this product.
Subcutaneous
STELARA SOLUTION FOR INJECTION IN PRE-FILLED PEN 90MG/1ML [SIN17103P]*
STELARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 45 MG/0.5ML [SIN13995P]*
STELARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 90 MG/1 ML [SIN13996P]*
* Clinical information is available for this product.
